Jump to content

Homarylamine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:22, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Homarylamine
Clinical data
Other names1,3-benzodioxolyl-N-methyl-5-ethanamine;
3,4-methylenedioxy-N-methyl-2-phenylethylamine;
Norlobivine
Routes of
administration
Various
Identifiers
  • 2-(1,3-Benzodioxol-5-yl)-N-methylethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO2
Molar mass179.219 g·mol−1
3D model (JSmol)
  • CNCCC1=CC2=C(C=C1)OCO2
  • InChI=1S/C10H13NO2/c1-11-5-4-8-2-3-9-10(6-8)13-7-12-9/h2-3,6,11H,4-5,7H2,1H3
  • Key:OPJOMVMFYOUDPK-UHFFFAOYSA-N
  (verify)

Homarylamine (INN;[1] also known as 3,4-methylenedioxy-N-methylphenethylamine and MDMPEA) is a substituted phenethylamine. It is the N-methylated analog of MDPEA. Homoarylamine was patented as an antitussive in 1956,[2] but has never been used medically as such.

Reactions

Reaction of homoarylamine with formaldehyde gives hydrastinine.

See also

  • Hydrastine, an alkaloid derivative of homarylamine

References

  1. ^ "International Non-Proprietary Names for Pharmaceutical Preparations" (PDF). Chronicle of the World Health Organization. 12 (3). 1958.
  2. ^ U.S. patent 2,820,739